| Symbol | CRBU |
|---|---|
| Name | CARIBOU BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2929 7TH STREET,SUITE 105, BERKELEY, California, 94710, United States |
| Telephone | +1 510 982-6030 |
| Fax | — |
| — | |
| Website | https://www.cariboubio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001619856 |
| Description | Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Additional info from NASDAQ: |
New Form DEFR14A - Caribou Biosciences, Inc. <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 0001619856-26-000028 <b>Size:</b> 2 MB
Read moreNew Form DEFA14A - Caribou Biosciences, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001619856-26-000023 <b>Size:</b> 437 KB
Read moreNew Form DEF 14A - Caribou Biosciences, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001619856-26-000022 <b>Size:</b> 2 MB
Read more(90% Positive) CARIBOU BIOSCIENCES, INC. (CRBU) Announces Enrollment Update for dose Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read more(30% Negative) CARIBOU BIOSCIENCES, INC. (CRBU) Reports Q1 2026 Financial Results
Read moreNew Form S-8 - Caribou Biosciences, Inc. <b>Filed:</b> 2026-03-05 <b>AccNo:</b> 0001193125-26-094237 <b>Size:</b> 192 KB
Read moreKelly Timothy P 🔴 sold 6.2K shares of Caribou Biosciences, Inc. (CRBU) at $1.93 Transaction Date: Feb 25, 2026 | Filing ID: 000004
Read more📋 RUHI AHMAD KHAN (Officer) plans to sell 7K shares of CARIBOU BIOSCIENCES, INC. (at $1.96 each, total $14K) Filed: Feb 25, 2026 | ID: 000005
Read more📋 BARBARA G MCCLUNG (Officer) plans to sell 7K shares of CARIBOU BIOSCIENCES, INC. (at $1.96 each, total $14K) Filed: Feb 25, 2026 | ID: 000007
Read more📋 TIMOTHY KELLY (Officer) plans to sell 6K shares of CARIBOU BIOSCIENCES, INC. (at $1.93 each, total $12K) Filed: Feb 25, 2026 | ID: 001807
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06752876 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refract… | Phase1 | Systemic Lupus Erythematosus | Withdrawn | 2027-12-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapse… | Phase1 | Acute Myeloid Leukemia, in Relapse | Terminated | 2024-02-08 | 2025-05-30 | ClinicalTrials.gov |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed… | Phase1 | Relapsed/Refractory Multiple Myeloma | Recruiting | 2023-02-06 | 2027-12-01 | ClinicalTrials.gov |
| NCT05332054 | Long-Term Follow-up Study | — | Lymphoma, Non-Hodgkin | Enrolling_By_Invitation | 2022-03-16 | 2041-12-01 | ClinicalTrials.gov |
| NCT04637763 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B… | Phase1 | Lymphoma, Non-Hodgkin | Recruiting | 2021-05-26 | 2025-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Fludarabine | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | RECRUITING | NCT04637763 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | RECRUITING | NCT04637763 |
| CB-010 | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | RECRUITING | NCT04637763 |
| CB-012 | Other | Phase PHASE1 | Acute Myeloid Leukemia, in Relapse | TERMINATED | NCT06128044 |
| CB-011 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | RECRUITING | NCT05722418 |
| Caribou-sponsored investigational therapy | Drug | Preclinical | Lymphoma, Non-Hodgkin | ENROLLING_BY_INVITATION | NCT05332054 |
| CB-012 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia, in Relapse | TERMINATED | NCT06128044 |
| CB-011 | BIOLOGICAL | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | RECRUITING | NCT05722418 |
| Caribou-sponsored investigational therapy | BIOLOGICAL | Preclinical | Lymphoma, Non-Hodgkin | ENROLLING_BY_INVITATION | NCT05332054 |
| Fludarabine | DRUG | Phase PHASE1 | Lymphoma, Non-Hodgkin | RECRUITING | NCT04637763 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Lymphoma, Non-Hodgkin | RECRUITING | NCT04637763 |
| CB-010 | DRUG | Phase PHASE1 | Systemic Lupus Erythematosus | WITHDRAWN | NCT06752876 |